![Leerink Partners Biopharma - Two women lab technicians looking at a computer screen](https://leerink.com/wp-content/uploads/2024/04/Biopharma-Header_CMP_587802854.jpg.webp)
OUR FOCUS
Committed to Successful Outcomes
One of the Healthcare industry’s most active subsectors, Biopharma draws strong corporate and investor interest in the development of novel medicines to treat significant unmet medical needs. Having a reliable, ongoing source of capital is key to funding the lengthy process of bringing therapies to market.
Investors and corporate clients repeatedly turn to Leerink Partners’ experience and expertise to unlock the growth potential of innovative biopharma companies.
Recent transactions
![Avidity Logo](https://leerink.com/wp-content/uploads/2024/06/Avidity-2024-1024x559.jpg.webp)
$300 Million
Joint Bookrunner
Follow-On
August 2024
![](https://leerink.com/wp-content/uploads/2024/08/AnaptysBio-2024-1024x559.jpg.webp)
$100 Million
Joint Bookrunner
Follow-On
August 2024
![](https://leerink.com/wp-content/uploads/2024/05/scPharmaceuticals-2022-1024x559.jpg.webp)
$50 Million
Joint Bookrunner
Follow-On
August 2024
![](https://leerink.com/wp-content/uploads/2024/02/Tenaya-Therapeutics-2024-300x164-1.jpg.webp)
$45 Million
Exclusive Financial Advisor
Credit Facility with SVB
August 2024